Source:http://linkedlifedata.com/resource/pubmed/id/20729915
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
47
|
pubmed:dateCreated |
2010-11-25
|
pubmed:abstractText |
In different human carcinoma types, mast cell infiltrate increases with respect to normal tissue and mast cell density correlates with a bad prognosis. To assess the role of mast cells in human thyroid cancer, we compared the density of tryptase-positive mast cells in 96 papillary thyroid carcinomas (PTCs) versus normal thyroid tissue from 14 healthy individuals. Mast cell density was higher in 95% of PTCs (n=91) than in control tissue. Mast cell infiltrate correlated with extrathyroidal extension (P=0.0005) of PTCs. We show that thyroid cancer cell-line-derived soluble factors induce mast cell activation and chemoattraction in vitro. Different mast cell lines (HMC-1 and LAD2) and primary human lung mast cells induced thyroid cancer cell invasive ability, survival and DNA synthesis in vitro. The latter effect was mainly mediated by three mast-cell-derived mediators: histamine, and chemokines CXCL1/GRO? and CXCL10/IP10. We show that xenografts of thyroid carcinoma cells (8505-C) could recruit mast cells injected into the tail vein of mice. Co-injection of human mast cells accelerated the growth of thyroid cancer cell (8505-C) xenografts in athymic mice. This effect was mediated by increased tumor vascularization and proliferation, and was reverted by treating mice with sodium cromoglycate (Cromolyn), a specific mast cell inhibitor. In conclusion, our study data suggest that mast cells are recruited into thyroid carcinomas and promote proliferation, survival and invasive ability of cancer cells, thereby contributing to thyroid carcinoma growth and invasiveness.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Nov
|
pubmed:issn |
1476-5594
|
pubmed:author |
pubmed-author:AvillaEE,
pubmed-author:BasoloFF,
pubmed-author:GaldieroM RMR,
pubmed-author:GuarinoVV,
pubmed-author:LiottiFF,
pubmed-author:MaroneGG,
pubmed-author:MelilloR MRM,
pubmed-author:PreveteNN,
pubmed-author:RossiF WFW,
pubmed-author:SantoroMM,
pubmed-author:UgoliniCC,
pubmed-author:de PaulisAA
|
pubmed:issnType |
Electronic
|
pubmed:day |
25
|
pubmed:volume |
29
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
6203-15
|
pubmed:meshHeading |
pubmed-meshheading:20729915-Animals,
pubmed-meshheading:20729915-Cell Count,
pubmed-meshheading:20729915-Cell Line, Tumor,
pubmed-meshheading:20729915-Cell Proliferation,
pubmed-meshheading:20729915-Cell Survival,
pubmed-meshheading:20729915-Cell Transformation, Neoplastic,
pubmed-meshheading:20729915-Humans,
pubmed-meshheading:20729915-Male,
pubmed-meshheading:20729915-Mast Cells,
pubmed-meshheading:20729915-Mice,
pubmed-meshheading:20729915-Mice, Inbred BALB C,
pubmed-meshheading:20729915-Neoplasm Invasiveness,
pubmed-meshheading:20729915-Neoplasm Transplantation,
pubmed-meshheading:20729915-Prognosis,
pubmed-meshheading:20729915-Thyroid Neoplasms,
pubmed-meshheading:20729915-Vascular Endothelial Growth Factor A
|
pubmed:year |
2010
|
pubmed:articleTitle |
Mast cells have a protumorigenic role in human thyroid cancer.
|
pubmed:affiliation |
Dipartimento di Biologia e Patologia Cellulare e Molecolare, Istituto di Endocrinologia ed Oncologia Sperimentale del CNR, Naples, Italy. rosmelil@unina.it
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|